Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

End-to-end automation of organ-on-a-chip culture and drug testing: Enhancing scalability and expandability.

SLAS technology·2026
Same author

Automated and scalable expansion of human liver organoids for translational applications.

Journal of translational medicine·2026
Same author

Human liver-derived organoids recapitulate Oropouche virus infection and manifestation, enabling antiviral drug discovery.

Cell reports. Medicine·2026
Same author

Functional characterization of BAP1 mutations in genome edited cholangiocarcinoma organoids: Role in cell death and drug responses.

iScience·2026
Same author

Beyond Decellularization: Remnant Mitochondrial DNA Can Act as Hidden Damage-Associated Molecular Pattern.

Bioengineering (Basel, Switzerland)·2026
Same author

Biological feature-based machine learning in histopathological images: a systematic review.

Journal of pathology informatics·2026

Related Experiment Video

Updated: Jun 26, 2026

A Biomimetic Model for Liver Cancer to Study Tumor-Stroma Interactions in a 3D Environment with Tunable Bio-Physical Properties
08:40

A Biomimetic Model for Liver Cancer to Study Tumor-Stroma Interactions in a 3D Environment with Tunable Bio-Physical Properties

Published on: August 7, 2020

6.7K

Modeling hepatocellular carcinoma and its microenvironment on a chip.

Orsola Mocellin1, Stéphane Treillard1, Abbie Robinson1

  • 1MIMETAS BV, De Limes 7, NL-2342DH, Oegstgeest, The Netherlands.

Cell Death Discovery
|December 29, 2025
PubMed
Summary

Advanced hepatocellular carcinoma (HCC) patient-derived chip models revealed that standard therapies did not impact tumor cells, underscoring the need for novel drug discovery approaches. These models effectively evaluated drug responses in the tumor microenvironment.

More Related Videos

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.9K
Author Spotlight: Investigating Liver Cancer Pathogenesis Using Patient-Derived Organoids
07:25

Author Spotlight: Investigating Liver Cancer Pathogenesis Using Patient-Derived Organoids

Published on: August 18, 2023

2.4K

Related Experiment Videos

Last Updated: Jun 26, 2026

A Biomimetic Model for Liver Cancer to Study Tumor-Stroma Interactions in a 3D Environment with Tunable Bio-Physical Properties
08:40

A Biomimetic Model for Liver Cancer to Study Tumor-Stroma Interactions in a 3D Environment with Tunable Bio-Physical Properties

Published on: August 7, 2020

6.7K
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.9K
Author Spotlight: Investigating Liver Cancer Pathogenesis Using Patient-Derived Organoids
07:25

Author Spotlight: Investigating Liver Cancer Pathogenesis Using Patient-Derived Organoids

Published on: August 18, 2023

2.4K

Area of Science:

  • Oncology
  • Biotechnology
  • Drug Discovery

Background:

  • Hepatocellular carcinoma (HCC) is a prevalent liver cancer with increasing incidence, linked to advanced liver disease.
  • The tumor microenvironment, including cellular stroma and vasculature, critically influences HCC progression and treatment response.
  • Developing advanced models is crucial for early-stage drug and target discovery in HCC.

Purpose of the Study:

  • To conduct a phenotypic screen using a vascularized hepatocellular carcinoma patient-derived chip (PDChip) model.
  • To assess the efficacy of 28 treatment conditions on primary HCC tumors and cell lines within the PDChip model.
  • To evaluate drug effects on tumor cell viability, tumor-associated vasculature, and chemokine/cytokine profiles.

Main Methods:

  • Utilized approximately 1200 HCC PDChips derived from 8 primary HCC tumors and 2 cell lines.
  • Cultured PDChips under perfusion flow and exposed them to various treatment conditions.
  • Assessed outcomes including cell viability, vascular bed organization, and changes in chemokine and cytokine release.

Main Results:

  • Standard-of-care therapies (sorafenib, lenvatinib) reduced viability but did not affect HCC tumor cells in the PDChip model.
  • Atorvastatin decreased PDChip viability but did not alter vascular bed organization.
  • Several tested drugs modulated chemokine and cytokine release, with notable effects on IL6 levels.

Conclusions:

  • HCC PDChip models provide a robust platform for evaluating drug responses within the tumor and its microenvironment.
  • These models are valuable for preclinical research, aiding in disease understanding and the development of novel HCC therapeutics.
  • The study highlights limitations of current therapies and the potential of new drug candidates in modulating the HCC microenvironment.